CEbiotech.com - Central European Biotechnology Portal
be visible on the BioBusiness market                  ISSN 2300-0228
Most popular
searches

All articles

Filters:
Show search box
2015-03-25
Green light for Novartis drug “Jakavi” for rare blood cancer treatment

Green light for Novartis drug “Jakavi” for rare blood cancer treatment

Novartis drug “Jakavi” has been approved by the European Commission for the therapy of rare blood cancer, polycythemia vera. It is the first approved targeted drug for treatment of this disease and it gives hope for patients unresponsive to standard therapy with hydroxyurea.... Read more
Tags drug , cancer , eu , Novartis , targeted therapy , approval